FDA Approves DAPAGLIFLOZIN AND SAXAGLIPTIN — Novadoz Pharmaceuticals LLC

# FDA Approves Generic Version of Dapagliflozin and Saxagliptin Combination Novadoz Pharmaceuticals LLC has received FDA approval for a generic formulation of dapagliflozin and saxagliptin, an oral combination therapy for type 2 diabetes, potentially expanding access to the dual-action treatment and intensifying price competition in the competitive diabetes medication market. The approval of this generic version could meaningfully reduce treatment costs for patients while capturing market share from branded alternatives, benefiting both payors and healthcare systems seeking cost-effective diabetes management solutions.